Delving into the Latest Updates on Zhuhai Tengbai Pharmaceutical Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Zhuhai Tengbai Pharmaceutical Co., Ltd. is a manufacturer specializing in the research and development of new anti-cancer drugs. The main biopharmaceuticals developed have the effect of inhibiting angiogenesis activity as well as disrupting integrin functions. They also have inhibitory effects on ion channels and micro-nucleotides, achieving a "multi-target" design with one drug. This allows for a comprehensive and effective suppression of the recurrence and metastasis of various tumors.

Tags

Neoplasms

Digestive System Disorders

Recombinant polypeptide

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2

Top 5 Drug Type	Count

Small molecule drug	1
Recombinant polypeptide	1

Top 5 Target	Count

Integrin	2

主要目的：评价TB01在晚期结直肠癌患者中的抗肿瘤效应。次要目的： 1) 评价 TB01在晚期结直肠癌患者中的药代动力学（ PK）特征 2）评价 TB01在晚期结直肠癌患者中的安全性及耐受性。探索性目的： 1) 探索肿瘤组织中整合素的表达情况与疾病预后的相关性； 2) 探索体内细胞因子及其受体（VEGF、VEGFR）在用药前后的变化及其与疾病预后的相关性； 3) 探索TB01在晚期结肠癌患者中的免疫原性及抗药抗体（ADA）产生对PK、有效性和安全性的影响。

[Translation]

Primary purpose: To evaluate the anti-tumor effect of TB01 in patients with advanced colorectal cancer. Secondary purpose: 1) To evaluate the pharmacokinetic (PK) characteristics of TB01 in patients with advanced colorectal cancer 2) To evaluate the safety and tolerability of TB01 in patients with advanced colorectal cancer. Exploratory purpose: 1) To explore the correlation between the expression of integrins in tumor tissues and disease prognosis; 2) To explore the changes of cytokines and their receptors (VEGF, VEGFR) in the body before and after medication and their correlation with disease prognosis; 3) To explore the immunogenicity of TB01 in patients with advanced colon cancer and the effects of anti-drug antibody (ADA) production on PK, efficacy and safety.

Start Date-

Sponsor / Collaborator

Zhuhai Tengbai Pharmaceutical Co., Ltd.

CTR20213196 / CompletedPhase 1

评估注射用HYD-PEP06在实体瘤患者中安全性、耐受性和药代动力学—一项单中心、单臂、单次及多次给药的I期临床试验

[Translation] Evaluating the safety, tolerability and pharmacokinetics of HYD-PEP06 for injection in patients with solid tumors - a single-center, single-arm, single- and multiple-dose Phase I clinical trial

主要目的评价注射用HYD-PEP06在晚期实体瘤患者中单次给药及多次给药的耐受性和安全性，确定其最大耐受剂量（MTD）和剂量限制性毒性（DLT）。次要目的（1）评价注射用HYD-PEP06在晚期实体瘤患者中的药代动力学特征；（2）初步评估注射用HYD-PEP06治疗晚期实体瘤患者的有效性；探索性目的（1）初步探索注射用HYD-PEP06在人体的免疫原性反应及抗药抗体产生对PK/PD、有效性和安全性的影响；（2）初步探索注射用HYD-PEP06对细胞因子EGF/VEGF的影响。

[Translation]

Main purpose To evaluate the tolerability and safety of single and multiple doses of HYD-PEP06 for injection in patients with advanced solid tumors, and to determine its maximum tolerated dose (MTD) and dose-limiting toxicity (DLT). Secondary purpose (1) To evaluate the pharmacokinetic characteristics of HYD-PEP06 for injection in patients with advanced solid tumors; (2) To preliminarily evaluate the efficacy of HYD-PEP06 for injection in the treatment of patients with advanced solid tumors; Exploratory purpose (1) To preliminarily explore the effects of the immunogenic response and anti-drug antibody production of HYD-PEP06 for injection in humans on PK/PD, efficacy and safety; (2) To preliminarily explore the effects of HYD-PEP06 for injection on cytokines EGF/VEGF.

Start Date03 Apr 2020

Sponsor / Collaborator

Zhuhai Tengbai Pharmaceutical Co., Ltd.

100 Clinical Results associated with Zhuhai Tengbai Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Zhuhai Tengbai Pharmaceutical Co., Ltd.

Login to view more data

1

Literatures (Medical) associated with Zhuhai Tengbai Pharmaceutical Co., Ltd.

01 Apr 2023·Acta Pharmaceutica Sinica B

Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria

Article

Author: Li, Xiaokang ; Xu, Yixiang ; Chen, Feng ; Zhang, Chao ; Cheng, Zhiyang ; Zhao, Jinlong ; Zhou, Luoyifan ; Huang, Yunyuan ; Duan, Hao ; Jiang, Kai ; Li, Jian ; Cheng, Jiaxing ; Yang, Xinchun ; Xiang, Yaozu ; Chen, Xin

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been reapproved for heart failure (HF) therapy in patients with and without diabetes. However, the initial glucose-lowering indication of SGLT2i has impeded their uses in cardiovascular clinical practice. A challenge of SGLT2i then becomes how to separate their anti-HF activity from glucose-lowering side-effect. To address this issue, we conducted structural repurposing of EMPA, a representative SGLT2 inhibitor, to strengthen anti-HF activity and reduce the SGLT2-inhibitory activity according to structural basis of inhibition of SGLT2. Compared to EMPA, the optimal derivative JX01, which was produced by methylation of C2-OH of the glucose ring, exhibited weaker SGLT2-inhibitory activity (IC₅₀ > 100 nmol/L), and lower glycosuria and glucose-lowering side-effect, better NHE1-inhibitory activity and cardioprotective effect in HF mice. Furthermore, JX01 showed good safety profiles in respect of single-dose/repeat-dose toxicity and hERG activity, and good pharmacokinetic properties in both mouse and rat species. Collectively, the present study provided a paradigm of drug repurposing to discover novel anti-HF drugs, and indirectly demonstrated that SGLT2-independent molecular mechanisms play an important role in cardioprotective effects of SGLT2 inhibitors.

100 Deals associated with Zhuhai Tengbai Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Zhuhai Tengbai Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Phase 2 Clinical

Login to view more data